Goldman Sachs Sell-side卖方

Eli Lilly & Co. (LLY) 2Q26 Earnings First Take Another Impressive Beat and Raise

Aug 6, 20268 pages页

From the report报告摘录Earnings Beat & Guidance Surge: $23.0bn revenue (+$2.3bn vs. consensus), $2.5bn top-line guidance increase (range $82bn-$85bn → $85bn-$87bn), driven by Mounjaro (+10%/+10%), Zepbound (+8%/+6%), and US rebate adjustment…

Read the full report + PDF阅读全文与 PDF

The full summary (3 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（3 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →